HealthTech #4. The commoditization of genome sequencing and the opportunities for prevention

The mass affordability of sequencing enables a paradigm shift from sequencing only those with risk factors (such as someone's family history or medical symptoms) to sequencing proactively to identify risk factors. It will allow every individual to build up genomic data capital, opening the door for new applications and business models across health insurance, care delivery, and everyday life. New approvals & patents - Ava, a Swiss digital healthcare company focused on women's reproductive health, announced that the United States Food and Drug Administration (FDA) clearance for its fertility tracking wearable. BrainQ, an Israeli start-up, announced that the FDA has designated its AI-powered electromagnetic field therapy that aims to enhance recovery and reduce disability after neurological damage caused by stroke as a Breakthrough Device, giving access to the new Medicare Coverage of Innovative Technology (MCIT) pathway. Voluntis (French DTx) announced the issuance of a new patent by the European Patent Office (EPO) for intelligent patient support in drug dosing applied in the field of diabetes for insulin titration support.